Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.
Artikel in diesem Bereich werden auf Englisch angezeigt.
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
Lesen Sie auch
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
Global stock markets bounce higher; government bond yields tumble as oil slides – business live
‘She says it’s just money’: My friend pays for everything. I should be grateful, but I can’t stand her anymore.
